Charles Lieber's Transition to Brain-Computer Interface Research in China

Charles Lieber is one of the best-known names in nanoscience, but his career took a dramatic turn after a federal conviction in the United States. Once a leading Harvard chemistry professor, Lieber was convicted in 2021 of making false statements to federal authorities and tax-related offences tied to payments from China. Today, he is back in the lab in Shenzhen, where he is leading state-backed brain–computer interface research at i-BRAIN, part of the Shenzhen Medical Academy of Research and Translation. The field is medically promising but also strategically sensitive, which is why his move to China has drawn attention.

Lieber built a long and influential career at Harvard University, joining the faculty in 1991 and later serving as chair of the chemistry and chemical biology department from 2015 to 2020. He held the prestigious Joshua and Beth Friedman University Professorship, one of Harvard’s highest academic honours. Over three decades, he became a leading figure in nanoscience, publishing hundreds of peer-reviewed papers and holding dozens of patents. His research focused on nanoscale materials and nanoelectronics, particularly devices capable of interfacing with biological systems, including early work relevant to neural interfaces and brain–computer technologies. In December 2021, a federal jury convicted him of making false statements to federal authorities, filing false tax returns and failing to disclose foreign bank accounts. In April 2023, he was sentenced to time served, six months of home confinement, a $50,000 fine and restitution to the Internal Revenue Service. The case involved undisclosed participation in China’s Thousand Talents Plan and payments from a Chinese university.

Lieber’s move to Shenzhen marked a striking new chapter in a career already defined by high-stakes science. In April 2025, he arrived in the city and took charge of i-BRAIN, the Institute for Brain Research, Advanced Interfaces and Neurotechnologies, which operates under the Shenzhen Medical Academy of Research and Translation (SMART). There, he serves as founding director and chair professor. His lab reportedly has access to advanced nanofabrication tools and primate research facilities, giving him resources that were not available to him in the same form at Harvard. For a scientist long associated with nanoscale electronics, the setting is unusually well suited to the next phase of his work. The field he is now helping lead is brain-computer interfaces, or BCIs, which aim to translate brain activity into signals that computers can read and use. That technology already has medical promise. Researchers are exploring it for people with ALS, paralysis and speech loss, and recent advances have shown that neural signals can be turned into speech or used to control devices in limited ways. The field is moving steadily from laboratory experiments towards clinical applications. China has made BCIs a priority area. In 2026, it approved a commercial BCI medical device designed to help people with quadriplegia regain hand-grasping ability, and the technology has been identified in national planning as a future industry. That policy support helps explain why Lieber’s presence matters. He brings deep experience in nanofabrication, neural interfaces and advanced materials, the kind of expertise that can accelerate a research field with both humanitarian and strategic value. That is also why his new role remains controversial. Lieber is not simply a scientist starting over in a new country. He is a researcher who was convicted in the United States over false statements linked to China-related payments and affiliations, and he is now working inside a state-backed Chinese research system that is investing heavily in emerging technologies. His story sits at the point where science, geopolitics and technological competition meet, making him one of the most closely watched figures in the global race to link the brain with machines.